Nordea Investment Management AB increased its position in Vir Biotechnology, Inc. (NASDAQ:VIR Free Report) by 2.3% in the 2nd quarter, according to its most recent 13F filing with the...
Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV vaccine Phase 1 trial supported by the Bill & Melinda Gates Foundation...
Vir Biotechnology (NASDAQ:VIR Get Free Report) was downgraded by research analysts at Bank of America from a buy rating to a neutral rating in a report released on...
Vir Biotechnology, Inc. (NASDAQ:VIR Get Free Report) shares hit a new 52-week low during trading on Tuesday . The stock traded as low as $12.10 and last traded at $12.15, with a volume of...
This indicator may be signaling that VIR's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
Investors considering a purchase of Vir Biotechnology Inc (VIR) stock, but tentative about paying the going market price of 12.21/share, might benefit from considering selling puts among the...
Guggenheim Capital LLC raised its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR Free Report) by 194.5% in the 1st quarter, according to the company in its most recent 13F filing with the...
Swiss National Bank trimmed its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR Free Report) by 10.3% during the first quarter, according to its most recent disclosure with the Securities...
This indicator may be signaling that VIR's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...